Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma



Summary

Adrenocortical carcinoma (ACC) is an aggressive cancer with limited treatment options. This research identifies Delta-like ligand 1 (DLK1), a Notch ligand, as a promising immunotherapeutic target in ACC. DLK1 promotes tumor cell plasticity, allowing ACC cells to adapt and resist chemotherapy. Blocking DLK1 not only inhibits tumor growth directly but also enhances immune cell infiltration into the tumor, making it more susceptible to immunotherapy. Targeting DLK1 could therefore overcome chemoresistance and improve treatment outcomes for ACC patients by simultaneously attacking tumor cells and stimulating the immune system.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!